| Name | Title | Contact Details |
|---|
Cytel enables decision-makers in the life sciences to unlock the full potential of their products. From navigating uncertainty to proving value, Cytel`s 30 years of global expertise in consulting, data-driven analytics, and industry-leading software helps biotech and pharmaceutical companies transform intelligence into confident decisions. We have an uncompromising commitment to scientific rigor and high standards of operational excellence, which are channeled through our locations in North America, Europe, the United Kingdom, and Asia. Together, we enable our clients to deliver the therapies that propel humanity forward.
LTS offers a wealth of experience in adhesive formulation and coating technology to manufacture and supply specialty laminates intermediates for many applications. Our products are tailored to our customers' needs and are targeted for use in
NVE Pharmaceuticals is a Andover, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Covidien Ltd. (Covidien) is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Covidien is part of the local fabric of the communities in which we operate around the world. Our success is made possible through the dedication of our 43,000 employees, nearly two-thirds of whom work in 51 manufacturing facilities located in 18 countries. Every day, over 5,500 Covidien sales representatives meet the needs of our customers in 70 countries. In all, our Company derives 45% of its sales from outside the United States. Covidien, formerly Tyco Healthcare, is a medical equipment and supply company, incorporated in Dublin, Ireland, although its corporate offices are located in Mansfield, Massachusetts, USA. On June 29, 2007, Covidien became an independent publicly traded company after being spun off from Tyco International.
Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.